No Data
Sino Biopharmaceutical's Strategic Investment in Biotech
Sino biopharm (01177.HK): The fourth-generation EGFR inhibitor "TQB3002" has received clinical trial approval in the usa.
Graceful meeting November 14th | Sino Biopharm (01177.HK) announced that the group's independently developed fourth-generation EGFR inhibitor "TQB3002" has officially received the clinical trial application (IND) approval from the U.S. Food and Drug Administration (FDA) and is about to initiate Phase I clinical trials. Epidermal growth factor receptor (EGFR) is one of the genes with the highest mutation frequency. EGFR is also the most important driver gene in non-small cell lung cancer, with a mutation rate as high as 40%-50% in the East Asian population and 10%-20% in the Western population. TQB3002 acts by interacting with intracellular tyrosine
Express News | Sino Biopharmaceutical - Approval Granted for Clinical Trials of Egfr Inhibitor "Tqb3002" in US
Fangzheng Securities: Maintains a 'strong buy' rating on sino biopharm (01177), AnFangning approved for listing by the National Medical Products Administration.
sino biopharm's self-developed KRAS G12C inhibitor Gexolase tablets (trade name: Anfangning) have been approved for market by the National Medical Products Administration.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
No Data
No Data
